The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merck & Co Inc

NYSE: MRK
Last

(U.S.) $49.38

Today's change+0.79 +1.63%
Updated February 5 4:01 PM EST. Delayed by at least 15 minutes.
 

Merck & Co Inc

NYSE: MRK
Last

(U.S.) $49.38

Today's change+0.79 +1.63%
Updated February 5 4:01 PM EST. Delayed by at least 15 minutes.

Merck & Co Inc up sharply

Merck & Co Inc closed up sharply Friday, rallying (U.S.)$0.79 or 1.63% to (U.S.)$49.38. Over the last five days, shares have lost 2.55% and are down 6.51% for the last year to date. This security has underperformed the S&P 500 by 7.70% during the last year.

Key company metrics

  • Open(U.S.) $48.60
  • Previous close(U.S.) $48.59
  • High(U.S.) $49.72
  • Low(U.S.) $48.27
  • Bid / Ask-- / --
  • YTD % change-6.51%
  • Volume16,883,010
  • Average volume (10-day)14,606,455
  • Average volume (1-month)12,481,839
  • Average volume (3-month)11,910,584
  • 52-week range(U.S.) $45.69 to (U.S.) $61.70
  • Beta0.69
  • Trailing P/E31.58×
  • P/E 1 year forward13.32×
  • Forward PEG3.57×
  • Indicated annual dividend(U.S.) $1.84
  • Dividend yield3.73%
  • Trailing EPS(U.S.) $1.56
Updated February 5 4:01 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.29%

Based on its net profit margin of 11.29%, Merck & Co Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue10,0739,7859,42510,482
Total other revenue--------
Total revenue10,0739,7859,42510,482
Gross profit6,3826,1365,9616,838
Total cost of revenue3,6913,6493,4643,644
Total operating expense7,8468,2397,9899,306
Selling / general / administrative2,4292,4712,3382,787
Research & development1,4831,6551,7352,081
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)243464452794
Other operating expenses, total--------
Operating income2,2271,5461,4361,176
Interest income (expense), net non-operating-165-174-164-165
Gain (loss) on sale of assets--------
Other--------
Income before tax2,3978071,38111,811
Income after tax1,8316889587,327
Income tax, total5661194234,484
Net income1,8266879537,316
Total adjustments to net income--------
Net income before extra. items1,8266879537,316
Minority interest-5-1-5-11
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,8266879537,316
Inc. avail. to common incl. extra. items1,8266879537,316
Diluted net income1,8266879537,316
Dilution adjustment--------
Diluted weighted average shares2,8362,8502,8652,886
Diluted EPS excluding extraordinary itemsvalue per share0.640.240.332.54
Dividends per sharevalue per share0.450.450.450.44
Diluted normalized EPSvalue per share0.710.380.443.98